Intellia Therapeutics, Inc.NTLANASDAQ
LOADING
|||
Gross Profit Growth Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Year-over-year gross profit growth rate
Latest
-557.47%
↓ 6084% below average
Average (39q)
-9.01%
Historical baseline
Range
High:702.85%
Low:-557.47%
CAGR
+6.3%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -557.47% |
| Q2 2025 | -14.33% |
| Q1 2025 | 29.15% |
| Q4 2024 | 41.30% |
| Q3 2024 | 109.06% |
| Q2 2024 | -83.51% |
| Q1 2024 | 702.85% |
| Q4 2023 | -145.18% |
| Q3 2023 | 109.54% |
| Q2 2023 | -20.32% |
| Q1 2023 | 2.26% |
| Q4 2022 | -3.69% |
| Q3 2022 | -9.47% |
| Q2 2022 | 37.49% |
| Q1 2022 | -108.97% |
| Q4 2021 | -9.43% |
| Q3 2021 | -1.81% |
| Q2 2021 | -59.40% |
| Q1 2021 | -3.78% |
| Q4 2020 | -80.41% |
| Q3 2020 | 18.47% |
| Q2 2020 | 1.04% |
| Q1 2020 | -4.52% |
| Q4 2019 | -23.07% |
| Q3 2019 | -17.81% |
| Q2 2019 | -8.03% |
| Q1 2019 | -10.28% |
| Q4 2018 | 23.95% |
| Q3 2018 | -0.25% |
| Q2 2018 | -5.10% |
| Q1 2018 | -3.60% |
| Q4 2017 | -42.68% |
| Q3 2017 | -5.35% |
| Q2 2017 | -33.70% |
| Q1 2017 | -26.51% |
| Q4 2016 | -90.64% |
| Q3 2016 | 6.99% |
| Q2 2016 | 6.70% |
| Q1 2016 | -28.56% |
| Q4 2015 | -51.53% |